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Sllmmary 
Ras protooncogenes are activated by characteristic point mutations in a wide variety of malignancies. 
The expressed p21 ~  proteins are oncogenic by virtue of single substituted amino acids, usually 
at position 12 or 61 of the 189-residue p21 ~  protein. In the current study, the ability of class 
I major histocompatibility complex (MHC)-restricted T cells to recognize the altered segment 
of a transforming p21 ~ protein and to lyse cells transformed by the corresponding ras oncogene 
was examined. Synthetic ms peptides encompassing the common activating substitution of leucine 
for glutamine at position 61 were constructed with an amino acid motif appropriate for binding 
to the H-2K  b murine class I MHC molecule. Cytotoxic T lymphocytes (CTL) spedfic for bound 
ms leucine 61 peptide were elicited by in vitro immunization of normal lymphocytes with synthetic 
peptides. The ras peptide-induced CTL specifically lysed syngeneic fibroblasts  transformed by 
an activated ras gene encoding oncogenic p21  ~  protein containing the same single amino acid 
substitution. Thus, in some circumstances,  mutated p21 ~  protein can serve as a tumor-specific 
antigen. 
T 
umor-specific CTL can eradicate antigenic tumors in ex- 
perimental models (1). However, the use of specific CTL 
for cancer therapy has been limited by a paucity of defined 
tumor-specific antigens. In general, CTL recognize peptide 
fragments derived from endogenous  cellular proteins, processed 
internally, and presented at the cell surface bound to dass 
I MHC molecules (2-4). The appropriateness of any partic- 
ular protein to serve as a target for CTL depends upon whether 
the protein has antigenic segments with the proper molec- 
ular configuration or amino acid "motiP' to bind to dass I 
MHC molecules; whether the resultant peptide-MHC mo- 
lecular complex is presented at the cell surface in a concen- 
tration high enough to stimulate the antigen-specific TCR; 
and whether the peptide-MHC molecular complex is within 
the host T cell repertoire. Many tumor cells have been shown 
to harbor mutated pmtooncogenes  with transforming activity. 
Theoretically, the abnormal proteins encoded by mutated pro- 
tooncogene may contain peptide sequences as the result of 
activating mutations which are uniquely expressed in tumor 
cells and which potentially satisfy the necessary conditions 
for specific CTL recognition. 
Mutated  ms  protooncogenes are  particularly  prevalent 
among human tumors (5). Activating point mutations of ms 
predominantly occur within codons 12 and 61 and result in 
the expression of a limited number of oncogenic p21  ~ pro- 
teins bearing single amino acid substitutions (5). The muta- 
tions disrupt the normal signaling function of p21 '~ and 
contribute to malignant transformation (6,  7). Oncogenic 
p21 r~ protein bearing a single amino acid substitution re- 
presents a tumor-specific protein present only in transformed 
cells. The current study elicited  CTL specific for the mu- 
tated segment of a transforming p21  ~  protein by primary 
in vitro immunization with corresponding synthetic ras pep- 
tides and examined the ability of the mutated p21  ~ protein 
expressed by transformed cells to serve as a target for specific 
CTL lysis, i.e.,  to serve as a tumor-specific antigen. 
Materials and Methods 
Mice.  Female  C57B1/6  (B6) 1 mice,  6-12-wk-old,  were  ob- 
tained from The Jackson Laboratory (Bar Harbor, ME) and main- 
rained in the animal care facilities of the University of Washington. 
1 Abbreviations used in  this paper: BLKSVHD,  BLKSVHD.213; B6, 
C57B1/6;  CM,  culture  medium;  D b,  H-2Db;  K  b,  H-2Kb; T-OVA, 
trypsinized OVA. 
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transformed fibroblast  line of  B6 origin (8), was obtained from the 
American Type  Culture Collection  (Rockville,  MD). FBL-3,  a Friend 
virus-induced leukemia, and EL4, a chemically-induced  thymoma, 
both of B6 origin, were subcloned and maintained in our labora- 
tory (9). L cells transfected with H-2K  b (K  b) were a gift from Dr. 
S. Nathenson (Albert Einstein  School  of  Medicine, New York) (10). 
The TAP-2-deficient  cell line, RMA-S (derived from RBL-5 after 
mutagenization and selection with anti-H-2  b antiserum plus com- 
plement for loss of MHC class I expression), was a gift of Dr. C. 
Ohlen (Karolinska  Institute, Stockholm, Sweden) (11). All cell  lines 
were grown in culture medium (CM) consisting of RPMI 1640 
(GIBCO  BRL, Gaithersburg, MD)  supplemented with 2.5  x 
10 -s M 2-ME, 200 U/ml penicillin, 200 U/ml streptomycin, 10 
mM t-glutamine, and 10% FCS. Cells were kept in 25-ml flasks 
at 37~  in a humidified atmosphere with 5% CO2. 
PeFtides.  Synthetic  ras peptides  were synthesized  on a synthesizer 
(model 430A; Applied Biosystems, Foster City, CA) using BOC/ 
benzyl based chemistry. Individual peptides were cleaved  from the 
resin by reaction with hydrogen fluoride/anisole and purified by 
reversed phase chromatography. Characterization of the purified 
peptides was by amino acid analysis, analytical HPLC, and mass 
spectrometric determination of molecular weight. A mixture of 
36 overlapping ms peptides was synthesized in a single multiplex 
procedure. The amino acid sequence of p21  ~t61 from residue 53 
through 69 is LDILDTAGLEEYSAMRD.  The peptide mixture con- 
sisted of p53-61, -63, -64, -65, -66, -67, -68, -69; p54-61, -62, 
-63,  -64, -65,  -66,  -67,  -68,  -69;  p55-61, -62,  -63, -64,  -65, 
-66,  -67,  -68,  -69;  and p56-61, -62,  -63,  -64,  -65,  -66,  -67, 
-68, -69. To construct the peptide mixture arginine (corresponding 
to residue 68 of p21 ~) was coupled to aspartyl (residue 69) resin, 
then arginyl resin was introduced into the reaction vessel and me- 
thionine (residue 67) was coupled to the mixture of the two resins. 
This strategy of alternate coupling of an amino acid followed by 
the addition of the same amino acid resin to the mixture was con- 
tinued through L61. Residues G60, A59, T58, and D57 were cou- 
pled conventionally.  Then residues L56, I55, D54, and L53 were 
successively  coupled with resin being removed  after  each  cycle.  These 
four resulting resins with NH2-terminal L56, I55, D54, and L53 
were combined, cleaved with hydrogen fluoride, and the peptides 
were dissolved in aqueous acetic acid and chromatographed on 
Sephadex G-10. Synthetic OVA peptide p257-264 was a gift from 
Dr. S. Jameson (University of Washington, Seattle, WA). Peptide 
fragments of trypsinized OVA (T-OVA) were generated by tryptic 
digestion according to the method of Moore et al. (12). 
Plasmids  and Cell  Transfection.  The plasmid, pRSVL61, con- 
taining a synthetic ras  gene which encodes p21 cH  ..... with the 
single amino acid substitution of leucine for glutamine at residue 
61  was kindly provided by Dr. S. Nishimura (National Cancer 
Center Institute, Tokyo,  Japan) (13). The plasmid utilizes the LTR 
of Rous sarcoma  virus to enable  expression  of  the synthetic ras gene 
in eucaryotic  cells. The Homer 6 plasmid  containing the aph amino- 
glycoside  phosphotransferase  gene was obtained from Dr. O. Finn 
(Pittsburgh Cancer Institute, Pittsburgh, PA) (14). Plasmids were 
expanded in Esckerickia  coli  strain HB101 and purified by CsC1 
centrifugation.  BLKSVHD fibroblasts were cotransfected with 
pRSVL61 and Homer 6 using the calcium phosphate precipitation 
method ofSambrook et al. (15). Transformed  cells were cloned and 
expanded in selection medium containing G418 at 1 mg/ml. The 
presence of the transfected synthetic ms gene was confirmed by 
PCR amplification  and detection of  the 567-bp synthetic ms gene, 
using the primers ATGACCGAATACAAACTG  and AGACAG- 
AACGCATTTGCA. 
Peptide Binding Assay.  The ability of synthetic ms peptides to 
bind to and stabilize K  b class I MHC molecules on the surface of 
RMA-S cells was measured by immunofluorescence.  RMA-S cells 
were cultured for 2 h in the presence of CM alone or CM plus 
ms peptide (25 t~g/ml). Cells were washed and stained with FITC- 
conjugated anti-K  b (Pharmigen, San Diego, CA). Labeled cells 
were again washed and analyzed for fluorescence  on a FACStar  | 
II (Becton Dickinson & Co., San Jose, CA). Fluorescence  intensity 
was measured at 515-545 nm. 
In Vitro Immunization Protocol.  B6 spleen cells were immunized 
in vitro with the indicated peptide preparations according to previ- 
ously described  methods (16). Freshly  harvested  spleens were minced, 
washed, and suspended in CM at 5  x  106 cells per ml. A total 
of 5 x  107 spleen cells (vol. 10 ml) supplemented with sensitizing 
peptide (25/~g/ml) were incubated in upright 25 ml flasks for 7 d. 
The cultured cells were washed and tested in 4-h SlCr-release assays 
for the ability to lyse EL4 cells that had been preincubated for 2 h 
with designated targeting peptide (25 #g/ml). 
Generation  of T  Cell Lines and Clones.  T cell lines and clones 
were generated from in vitro-sensitized B6 spleen cells by repeti- 
tive stimulation of the primed spleen cells with synthetic ras pep- 
tides followed  by rlL2 as previously  described (17). Primed spleen 
cells were transferred to 24-well plates at 4  x  106 cells per well 
with irradiated syngeneic spleen cells (3,000 rad) at 2  x  106 cells 
per well and the sensitizing peptide (25/xg/ml). The lymphocytes 
were cultured for 5 d then split at 1:2 into fresh CM. On day 10, 
lymphocytes were restimulated with Ag. 2 d later cultures were 
split 1:2 and supplemented with human rlL-2 (5 U/ml),  gener- 
ously provided by Hoffmann-La Roche, Inc. (Nutley, NJ). There- 
after, T cells were maintained by periodic restimulation with Ag 
(5/*g/M) and irradiated syngeneic spleen cells, followed 2 d later 
by rlL-2 (5 U/ml). Cells were cloned by limiting dilution as previ- 
ously described (17). 
Cytotoxicity Assays.  The cytotoxic activity of dicited T ceils 
was measured by 4-h SlCr-release assays. Assays were performed 
as previously  described (9). Where indicated, target cells  were prein- 
cubated with the designated targeting or blocking peptides before 
use in SlCr-release assays. 
Results and Discussion 
Peptide binding with any particular MHC molecule is predi- 
cated on the component amino acids of the peptide being 
correctly aligned to the unique binding pockets of the MHC 
cleft (18). Key "anchoring" residues of antigenic peptides have 
been elucidated for a limited number of MHC molecules, 
including routine class I MHC molecules of the H-2  b haplo- 
type (19). The region of p21 r~ protein encompassing  the res- 
idue 61 activation site contains a putative Kb-binding motif 
(19), consisting of Y64 and M67. One of the most common 
mutations of residue 61 consists of the substitution of leu- 
cine for glutamine. To determine whether, in fact, fragments 
of aberrant p21r% which contain an altered residue 61, can 
bind to class I MHC molecules-the sine qua non of CTL 
generation- synthetic peptides corresponding to the altered 
segment of p21 r'~L61 were assayed for binding and stabiliza- 
tion of K b class I MHC molecules on the mutated cell line, 
RMA-S (H-2  b) ,11) 
Surface class I MHC molecules normally exist as trimo- 
lecular structures composed of class I H  chain, bound pep- 
tide and/Jz-microglobulin (20,  21). Both peptide and 32- 
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Figure  1.  Stabilization of K b expression on RMA-S by ms  L61 pep- 
tides. RMA-S cells were cultured with the indicated peptide, then evalu- 
ated by immunofluor~cent analysis for  K  b expression as described in 
Materials and Methods.  The data represents the difference between the 
mean fluor'-~cence  of cells cultured with the indicated peptide and the mean 
fluorescence of cells cultured without exogenously added peptide. 
microglobulin are necessary for stable expression of class I 
MHC molecules at the cell surface. RMA-S cells express low 
levels of surface class I MHC molecules, attributable to the 
impaired transport of endogenously processed peptides for 
association with class I H chains (22, 23). However,  provi- 
sion of exogenous peptides that can bind to the unoccupied 
antigen binding groove, stabilize  and enhance the expres- 
sion of cell surface class I MHC molecules (24). Accordingly, 
RMA-S cells were incubated with a variety of synthetic pep- 
tides corresponding to the amino acid sequence of p21 ~L6t 
and assayed for expression of K b (Fig.  1). Ras L61 peptides 
ranging from 7 to 12 residues  in length and extending to 
M67 in their COOH terminus (p61-67, p60-67, p59-67, 
p58-67, p57-67, and p56-67) each stabilized expression of 
K b on RMA-S to varying degrees. Maximal stabilization of 
K b was observed with the 9-mer p59-67 peptide at levels 
comparable to that achieved with a known Kb-binding pep- 
tide, OVA p257-264 (25). The p60-66 ras L61 peptide lacking 
the putative M67 anchoring determinant, did not stabilize 
K b expression. Moreover, normal ras Q61 peptide homologs 
containing the putative Y64 and M67 anchor residues did 
not stabilize K b expression,  indicating that the substitution 
of leucine for glutamine at residue 61 was important for the 
generation of a ras peptide segment capable of binding K b. 
The L61 residue may act as a secondary anchor residue that 
binds to a corresponding subpocket of the K b groove (18, 
26, 27). Alternatively,  the L61 residue may have conforma- 
tional effects that enable the dominant anchor residues to align 
properly for binding to K b. 
The ability of Kb-binding ras L61 peptides to elicit CTL 
of the H-2  b haplotype was examined. The generation of class 
I MHC-restricted CTL has classically required in vivo im- 
munization with stimulator cells that synthesize the nomi- 
nated target protein and that process and present the protein 
through the class I MHC pathway. Recently it has been shown 
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to be possible to prime CTL in vivo by immunization with 
peptides that exhibit appropriate class I MHC binding motifs 
(28-30), thereby circumventing the need to immunize with 
viable ceils synthesizing the nominated antigen. In a few in- 
stances, it has been possible to dicit CTL by priming with 
similar peptides in vitro, although CTL generated by pep- 
tide priming often fail to lyse ceils that synthesize the parental 
target protein. In initial experiments, individual Kb-binding 
ras L61 peptides were tested for the ability to immunize B6 
spleen cells in vitro. Multiple experiments to elicit CTL with 
individual Kb-binding ras L61 peptides ranging from 8 to 12 
mer in size proved unsuccessful. 
The generation of peptide-specific CTL response requires 
both peptide binding to class I MHC molecules and the pres- 
ence ofT cells with antigen-specific TCRs capable of recog- 
nizing that particular peptide-MHC complex. "Holes" in 
the T call repertoire may exist for particular peptides bound 
in particular configurations. To circumvent the possibility that 
the ras L61 peptides used in initial experiments were not of 
the appropriate size or configuration for the induction of CTL, 
a panel of 36 overlapping ras L61 peptides was synthesized 
and used in combination to immunize lymphocytes in vitro. 
The peptides ranged from 6 to 17 residues in length and were 
systematically staggered from the NHz and COOH termini 
(see Materials and Methods). The presumption was that mul- 
tiple CTL specific for several different peptide/K  b configu- 
rations would be elicited. Lymphocytes were cultured in vitro 
with the ras L61 peptide mixture and assayed for cytotox- 
icity. Ras L61 peptide-specific CTL were induced as evidenced 
by augmented lysis of syngeneic tumor cells (EL4) preincubated 
with the ras L61 peptide mixture compared to tumor cells 
alone (Table 1). The ras L61 peptide-specific CTL mediated 
enhanced lysis of tumor cells incubated with the sensitizing 
ras L61 peptide mixture but not with irrelevant peptide frag- 
ments of T-OVA. Conversely, CTL elicited by in vitro im- 
munization to T-OVA peptides mediated enhanced lysis of 
tumor cells incubated with T-OVA peptides but not with 
the ms L61 peptide mixture (Table 1). 
The specificity of the ras L61 peptide-induced CTL was 
further examined with individual ras L61 target peptides. A 
CTL line was established from in vitro-sensitized lympho- 
cytes that expressed the CD4-CD8 + cell surface phenotype 
and that lysed EL4 tumor cells in the presence of selected 
ras  L61  peptides  (Table  2).  Homologous peptides corre- 
sponding to normal p21 `~' protein, were unable to target 
lysis by the CTL line (Table 2). Moreover, irrelevant peptides 
with high affinity to K b did not sensitize targets for lysis by 
the CTL line (data not shown). Thus, the ras L61 peptide- 
induced CTL specifically recognized only L61-substituted ras 
peptides. 
The ms L61-spedfic CTL line strongly lysed targets pulsed 
with individual ras L61 peptides that stabilized  K b expres- 
sion, but not with ras L61 peptides that did not stabilize K b 
(Table 2). However, the degree of cytotoxicity directed against 
individual Kb-binding ras L61 peptide was not directly pro- 
portionate to the ability of the peptide to stabilize  K b on 
RMA-S. Smaller ras L61 peptides (7 and 8 mer), which were 
less effective than larger peptides in stabilizing K b (Fig.  1), Table  1.  Cytolytic Acitivity  of Lymphocytes Immunized 
In  Vitro with ras L61  Peptides 
Specific lysis 
Sensitizing  Targeting 
peptide  peptide  80:1  20:1  5:1 
% 
ras L61*  None*  36  s  15  3 
ms L61  ras L61  50  26  8 
ms L61  T-OVA  37  15  3 
T-OVA  None  37  14  4 
T-OVA  ras L61  37  12  4 
T-OVA  T-OVA  52  29  8 
* B6 spleen ceils were incubated for 7 d with the indicated peptides at 
25/~g/ml. ms L61 denotes the ms 1..61 Ix*pride  mixture and T-OVA denotes 
trypsinized  OVA, described in Materials and Methods. 
* stCr-labded EL4 ceils were preincubated for 2 h with the indicated pep- 
tide at 25/~g/ml, then used as targets. 
$ E/T ratio. 
were more effective than larger peptides in sensitizing target 
cells for specific killing (Table 2). Most of the tested peptides 
which targeted specific killing were not intentionally con- 
structed in the mixture of ms L61 peptides used for in vitro 
immunization. However, it is probable that such peptide frag- 
ments were present in the mixture as the result of partial 
synthesis and/or degradation (31). 
The MHC restriction of the ras L61 peptide-induced CTL 
was established by chromium release assays with H-2 D b and 
K 8  transfected  target  cells.  Ras  L61-specific  CTL  lysed 
peptide-treated targets that exclusively expressed K 8 (Table 
3) but not targets that expressed D b (data not shown). Coin- 
cubation  of  target  cells  with  a  synthetic  OVA  peptide 
(p257-264) with high affinity for K b (25), markedly reduced 
the ability of ras L61 peptides to sensitize syngeneic target 
cells for lysis by ras L61-specific CTL (Fig.  2). By contrast, 
normal ras peptides, p56-67 Q61 and p60-67 Q61, did not 
block the ability of homologous ms L61 peptides to sensitize 
targets for lysis, providing additional evidence that normal 
ras Q61  peptides do not bind to K b with high affinity. 
Under  normal  circumstances,  antigenic class  I  MHC- 
restricted peptide determinants are proteolytically excised from 
endogenously produced proteins (32).  Potentially antigenic 
determinants nested within an intact protein may be destroyed 
by inappropriate cleavage of proteins by proteases during an- 
tigen processing. Furthermore, competing or suppressive de- 
terminants at other sites within a protein may mask CTL 
recognition of a potentially antigenic peptide segment (33). 
To establish whether endogenously expressed p2r  *'L61 pro- 
tein could be processed and presented to enable CTL recog- 
nition of the mutated segment of the protein,  a fibroblast 
line of B6  origin  (H-2  b)  was  transfected with  the mam- 
malian expression vector pRSV-L61 encoding p21 c-m''~ pro- 
tein with the activating L61  substitution  (13) and used as 
a target in chromium release assays. The ms L61-specific CTL 
effectively lysed fibroblasts transformed  by the mutated c-Ha-ms 
L61 gene, but not untransfected fibroblasts nor other syn- 
geneic transformed ceils (Fig.  3). 
The current study demonstrates that peptide-specific  CTL 
dicited by primary in vitro immunization can lyse transformed 
ceUs on the basis  of the expression of an abnormal ras on- 
cogene. The conditions developed to allow elicitation of pep- 
tide-specific CTL were derived by empiric experimentation. 
Large numbers of responder cells were required, presumably 
to compensate for a low frequency of CTL precursors (16). 
The reasons for the failure to demonstrate priming to in- 
dividual ras L61 peptides, in light of the ability to prime to 
Table  2.  Lysis of EL4  Tumor  Cells Incubated with  Various Synthetic ras Peptides by ras L61  Peptide-induced CTL 
Specific lysis 
Targeting 
ras peptide  Amino acid sequence  40:1  20:1  10:1 
**  % 
ms L61*  76s  70  62 
#0-66  L61  G L  E  E  Y  S A  7  2  2 
p61-67L61  L  E  E  Y  S  A  M  81  76  67 
p60-67 L61  G  L  E  E  Y  S  A  M  72  59  55 
p59-67 L61  A  G L  E  E  Y  S  A  M  61  49  44 
p56-67 L61  L  D  T  A  G  L  E  E  Y  S  A  M  58  47  31 
p60-67Q61  G  Q  E  E  Y  S  A  M  5  4  2 
" The arrow denotes residue 61. 
* stCr-labeled EL4 cells were  preincubated  for 2 h with the indicated peptide (25/*g/ml) then used as targets. 
$ E/T ratio. 
476  Cytotoxic  T Lymphocytes  Specific  for  Mutated  p21~ Protein Table  3.  Lysis of H-2K  b Transfected Cells Incubated with  Various Synthetic ras Peptides by ras L61 Peptide-induced CTL 
Specific lysis 
Targeting 
ras peptide  Amino acid sequence  40:1  20:1  10:1  5:1 
4"  % 
ras L61'  55  s  49  45  37 
p60-66 L61  G  L  E  E  Y  S  A  4  3  3  2 
p61-67L61  L  E  E  Y  S  A  M  56  51  50  47 
p60-67 L61  G  L  E  E  Y  S  A  M  49  39  30  26 
p59-67 L61  A  G  L  E  E  Y  S  A  M  41  33  31  27 
p56-67 L61  L  D  T  A  G  L  E  E  Y  S  A  M  46  34  22  14 
p60-67 Q61  G  Q  E  E  Y  S  A  M  5  4  2  2 
* The arrow denotes residue 61. 
slCr-labeled L cells transfected  with K  b were preincubated for 2 h with the indicated peptide (50 #g/ml), then used as targets. 
s E/T ratio. 
the pepdde mixture, have not been experimentally determined. 
However, it is most likely that the ms L61 peptide mixture 
concurrently primed CD4 + T cells to provide requisite help 
for the elicitation of CD8 + CTL responses. Previous studies 
have shown that longer ms L61 pepddes are capable of didting 
Th cell responses  (17),  and many studies have emphasized 
the role of CD4 + T  cells in the generation of CTL (34). 
In vivo immunization with similar ms peptides should en- 
gender similar CTL responses,  with the caveat that little is 
known concerning the optimal methods to prime in vivo 
with class I MHC-binding peptides.  CTL specific for the 
mutated region of  p53 have been generated by in vivo priming 
(35).  It might be possible to generate ms-specific CTL by 
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Figure  2.  Inhibition  of ms L61 peptide-specific  cytotoxidty  by the K  b- 
binding ovalbumin  pepdde, OVA p257-264. SlCr-labeled  EL4 cells were 
incubated in serial dilutions  of either ms p60-67 L61 (open  slnnboh) or ms 
p56-67 L61 (closed  sjnnbo/s) pepddes  plus the indicated  competing  peptide 
(5/~g/ml) for 1 h, then used as targets in 4-h chromium  release assays. 
Competing peptides included: ms p60-67 Q61 (8 mer), ras p56--67 Q61 
(12 mer), and OVA p257-264. The data  represent the percent specific  lysis 
of the target cells by the ras L61-specific  CTL line. 
the use of recombinant vaccinia virus encoding relevant  ras 
proteins (36). However, antivaccinia responses may predom- 
inate, especially in previously primed individuals. Alterna- 
tively immunization with soluble protein has in some cir- 
cumstances been reported to predispose to the generation of 
primed CTL to proteins,  including p21  "~ (37). However, the 
use of in vitro priming, especially  if adaptable to humans, 
may allow a more precise determination of antigenic peptide 
epitopes and a more rapid determination of epitopes that are 
actually processed and presented by malignant cells. The fur- 
ther development of primary in vitro immunization may 
greatly hasten the realization of specific T  cell therapy for 
malignancy. 
The current study confirms that recognition of oncogenic 
ras proteins by mammalian CTL is possible.  The ability of 
CTL to lyse transformed ceils on the basis of the expression 
of an abnormal ras oncogene suggests that it might be feasible 
to define circumstances for eliciting and utilizing specific CTL 
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Figure 3.  Lysis  of p21~l-transformed cells by syngeneic  ms/.61- 
specific CTL. The ms L61 peptide-induced  CTL line  was assayed  for the 
ability to lyse the indicated target cells in 4-h chromium release assays. 
(BLKSVHD + ms L61) BLKSVHD  cells transformed  with the c-Ha-ras 
L61 oncogene. 
477  Peace et al. to treat ras oncogene-transformed malignancies. The deter- 
mination of whether ras-positive tumors elicit ras-spedfic im- 
mune responses and whether elicited immune responses affect 
tumor progression and/or the expression  of p21 '~' protein 
may allow the elucidation of the concept of immune surveil- 
lance and/or immunological escape at a defined molecular level. 
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